Compare LAW & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | NGNE |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | United States | United States |
| Employees | 577 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.6M | 327.8M |
| IPO Year | 2021 | 2014 |
| Metric | LAW | NGNE |
|---|---|---|
| Price | $4.16 | $19.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $8.00 | ★ $60.13 |
| AVG Volume (30 Days) | ★ 484.5K | 175.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $156,849,000.00 | $925,000.00 |
| Revenue This Year | $11.23 | N/A |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 8.29 | N/A |
| 52 Week Low | $2.45 | $6.88 |
| 52 Week High | $9.11 | $37.27 |
| Indicator | LAW | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 45.74 |
| Support Level | $3.92 | $19.44 |
| Resistance Level | $4.61 | $21.03 |
| Average True Range (ATR) | 0.27 | 1.74 |
| MACD | 0.07 | -0.47 |
| Stochastic Oscillator | 22.83 | 17.85 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.